A national, multicenter, secondary data use study evaluating efficacy and retention of first-line biologic treatment with tocilizumab in patients with rheumatoid arthritis in real-life setting: results from TURKBIO registry

Tocilizumab (TCZ) is a recombinant humanized monoclonal antibody that targets the IL-6 receptor. TCZ found to be efficacious and has a good tolerated safety profile in rheumatoid arthritis (RA) patients. The aim of this study was to describe the disease activity and retention rate in Turkish RA pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Yazici, Ayten, Özdemir Işık, Özlem, Dalkılıç, Ediz, Koca, Süleyman Serdar, Pehlivan, Yavuz, Şenel, Soner, Inanc, Nevsun, Akar, Servet, Yılmaz, Sema, Soysal Gündüz, Özgül, Cefle, Ayse, Karakaş, Ömer Fatih, Onen, Fatos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9767915/
https://www.ncbi.nlm.nih.gov/pubmed/36539458
http://dx.doi.org/10.1038/s41598-022-26106-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9767915/
https://www.ncbi.nlm.nih.gov/pubmed/36539458
http://dx.doi.org/10.1038/s41598-022-26106-0

Ejemplares similares